推荐产品
特异性
与人 GD2 神经节苷脂特异性反应。
应用
免疫组织化学（冷冻组织切片）（Cheresh et al.，1986）
培养细胞的免疫荧光
流式细胞术：每10E6个细胞1-2 μg
对GD2阳性细胞的细胞毒性（Mujoo et al., 1987, 1989）
最佳工作稀释度必须由最终用户确定。
培养细胞的免疫荧光
流式细胞术：每10E6个细胞1-2 μg
对GD2阳性细胞的细胞毒性（Mujoo et al., 1987, 1989）
最佳工作稀释度必须由最终用户确定。
抗双唾液酸神经节苷脂抗体，clone 14G2a 检测双唾液酸神经节苷脂 GD2 &的水平，已发表验证可用于 FC、IF、IH。
外形
形式：纯化
溶于0.02 M PB pH值7.6、0.25 M NaCl、含有0.1%叠氮化钠的细胞培养上清液。
其他说明
浓度：请参考批次特异性浓缩物的检验报告。
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Patrizia Garbati et al.
International journal of molecular sciences, 22(13) (2021-07-03)
High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride
Christian M Seitz et al.
Oncoimmunology, 9(1), 1683345-1683345 (2020-02-01)
Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression was confirmed
Martin V Kolev et al.
Journal of immunology (Baltimore, Md. : 1950), 184(11), 6035-6042 (2010-04-28)
Tumor cells escape clearance by complement by abundantly expressing CD59 and other membrane complement regulators. Recently, we designed a peptide derived from the neural-restrictive silencer factor (REST), REST68, which we showed to inhibit expression of CD59 in tumors lacking the
Hideki Yoshida et al.
Scientific reports, 10(1), 1199-1199 (2020-01-29)
β-1,4-N-Acetyl-Galactosaminyltransferase 1 (B4GALNT1) encodes the key enzyme B4GALNT1 to generate gangliosides GM2/GD2. GM2/GD2 gangliosides are surface glycolipids mainly found on brain neurons as well as peripheral nerves and skin melanocytes and are reported to exacerbate the malignant potential of melanomas.
Patrizia Garbati et al.
Biomedicines, 8(11) (2020-11-07)
To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门